The activation of mast cells in the lungs and skin is involved in diseases such as asthma and chronic spontaneous urticaria, where the KIT receptor tyrosine kinase is a key regulator of mast cell function.
Generate Biomedicines Inc. proved that enthusiasm hasn’t waned for TSLP as a target by pricing an IPO selling 25 million shares at $16 each for proceeds of $400 million. Generate’s lead compound is phase III-stage TSLP-targeting antibody GB-0895 and the company’s assigned Nasdaq ticker is GENB. The offering is expected to close on March 2.
Upstream Bio Inc.’s favorable top-line results from the phase II Valiant trial testing verekitug in adults with severe asthma were not enough to charm Wall Street, and shares of the firm (NASDAQ:UPB) closed Feb. 11 at $14.69, down $13.12, or 47%.
Australian respiratory imaging technology company 4dmedical Ltd. raised AU$150 million (US$105 million) in an institutional placement to accelerate U.S. adoption of its CT:VQ lung imaging software to bolster the company’s lead in software-based lung imaging.
The prevalence of asthma differs between men and women, and furthermore, the difference changes over the lifespan. “Asthma is more common in boys than girls, but more common in women than men,” Clare Lloyd told BioWorld. Females are particularly susceptible to asthma during developmental periods of hormonal changes, also known as puberty, pregnancy and menopause.
The prevalence of asthma differs between men and women, and furthermore, the difference changes over the lifespan. “Asthma is more common in boys than girls, but more common in women than men,” Clare Lloyd told BioWorld. Females are particularly susceptible to asthma during developmental periods of hormonal changes, also known as puberty, pregnancy and menopause.
Asthma is an inflammatory airway disease characterized by shortness of breath and wheezing, among others, with a varying global prevalence of 1%-18%. Both airway hyperresponsiveness and airway remodeling are two important features of the disease, where epithelial-mesenchymal transition (EMT) plays a critical role. Glucocorticoid induced 1 (GLCCI1) is a protein involved in glucocorticoid signaling that has gained interest in the field of asthma, where it has been shown to be downregulated in the lung tissues of mice with asthma and its overexpression has been found to alleviate airway remodeling.
Tianjin Tianyao Pharmaceuticals Co. Ltd. has identified glucocorticoid receptor (GR) agonists reported to be useful for the treatment of conjunctivitis, asthma, chronic obstructive pulmonary disease, allergic rhinitis, nasal polyps, Crohn’s disease, eczema and psoriasis.
Enanta Pharmaceuticals Inc. has announced a new immunology program and updated progress in its immunology pipeline. The company’s new program is focused on developing oral MRGPRX2 inhibitors for type 2 immune driven diseases, with an initial focus on chronic spontaneous urticaria and other mast cell-driven diseases.
